Literature DB >> 14755681

Par-4 inducible apoptosis in prostate cancer cells.

Sushma Gurumurthy1, Vivek M Rangnekar.   

Abstract

Prostate cancer is associated with the inability of prostatic epithelial cells to undergo apoptosis rather than with increased cell proliferation. Prostate apoptosis response-4 (Par-4) is a unique pro-apoptotic molecule that is capable of selectively inducing apoptosis in cancer cells when over-expressed, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. This review discusses the salient functions of Par-4 that can be harnessed to prostate cancer therapy. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755681     DOI: 10.1002/jcb.20000

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  15 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  Dynamics of the SPRY domain-containing SOCS box protein 2: flexibility of key functional loops.

Authors:  Shenggen Yao; Ming S Liu; Seth L Masters; Jian-Guo Zhang; Jeffrey J Babon; Nicos A Nicola; Sandra E Nicholson; Raymond S Norton
Journal:  Protein Sci       Date:  2006-11-06       Impact factor: 6.725

3.  Unraveling the molecular targets pertinent to junction restructuring events during spermatogenesis using the Adjudin-induced germ cell depletion model.

Authors:  Weiliang Xia; Dolores D Mruk; Will M Lee; C Yan Cheng
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

4.  Expression Pattern of the Pro-apoptotic Gene PAR-4 During the Morphogenesis of MCF-10A Human Mammary Epithelial Cells.

Authors:  Simone A de Bessa Garcia; Michelly C Pereira; Maria A Nagai
Journal:  Cancer Microenviron       Date:  2010-12-21

5.  Tumour-suppression activity of the proapoptotic regulator Par4.

Authors:  Isabel García-Cao; Angeles Duran; Manuel Collado; Maria J Carrascosa; Juan Martín-Caballero; Juana M Flores; Maria T Diaz-Meco; Jorge Moscat; Manuel Serrano
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807

Review 6.  A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4.

Authors:  Reyaz Ur Rasool; Debasis Nayak; Souneek Chakraborty; Archana Katoch; Mir Mohd Faheem; Hina Amin; Anindya Goswami
Journal:  Clin Exp Metastasis       Date:  2016-08-27       Impact factor: 5.150

Review 7.  Ubiquitous SPRY domains and their role in the skeletal type ryanodine receptor.

Authors:  Hanshen Tae; Marco G Casarotto; Angela Fay Dulhunty
Journal:  Eur Biophys J       Date:  2009-04-28       Impact factor: 1.733

8.  Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer.

Authors:  Kyungbo Kim; Pereira Araujo; Nikhil Hebbar; Ziyuan Zhou; Xirong Zheng; Fang Zheng; Vivek M Rangnekar; Chang-Guo Zhan
Journal:  Protein Eng Des Sel       Date:  2019-12-13       Impact factor: 1.650

9.  aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.

Authors:  Hitoshi Ishiguro; Kazunori Akimoto; Yoji Nagashima; Yasuyuki Kojima; Takeshi Sasaki; Yukari Ishiguro-Imagawa; Noboru Nakaigawa; Shigeo Ohno; Yoshinobu Kubota; Hiroji Uemura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-02       Impact factor: 11.205

10.  Changes in the gene expression programs of renal mesangial cells during diabetic nephropathy.

Authors:  Eric W Brunskill; S Steven Potter
Journal:  BMC Nephrol       Date:  2012-07-28       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.